ID   SK-MEL-24
AC   CVCL_0599
SY   Sk-Mel-24; SK Mel 24; SKMEL-24; SK-MEL24; SK-Mel24; SKMEL24; SKMel24; AQ-Mel
DR   BTO; BTO:0005861
DR   CLO; CLO_0009042
DR   EFO; EFO_0006487
DR   CLDB; cl7124
DR   ArrayExpress; E-MTAB-783
DR   ArrayExpress; E-MTAB-2706
DR   ArrayExpress; E-MTAB-2770
DR   ArrayExpress; E-MTAB-3610
DR   ATCC; HTB-71
DR   BioGRID_ORCS_Cell_line; 466
DR   BioSample; SAMN03473230
DR   BioSample; SAMN10988223
DR   cancercelllines; CVCL_0599
DR   Cell_Model_Passport; SIDM01106
DR   ChEMBL-Cells; CHEMBL3308324
DR   ChEMBL-Targets; CHEMBL2366314
DR   Cosmic; 687441
DR   Cosmic; 851405
DR   Cosmic; 909725
DR   Cosmic; 932997
DR   Cosmic; 1022274
DR   Cosmic; 1054858
DR   Cosmic; 1102581
DR   Cosmic; 1155265
DR   Cosmic; 1458965
DR   Cosmic; 1459651
DR   Cosmic; 1507625
DR   Cosmic; 1669140
DR   Cosmic; 1995634
DR   Cosmic-CLP; 909725
DR   DepMap; ACH-000822
DR   EGA; EGAS00001000610
DR   EGA; EGAS00001000978
DR   GDSC; 909725
DR   GEO; GSM784509
DR   GEO; GSM887583
DR   GEO; GSM888666
DR   GEO; GSM1670438
DR   GEO; GSM1671959
DR   GEO; GSM1671965
DR   GEO; GSM1671966
DR   GEO; GSM1671972
DR   GEO; GSM1671978
DR   GEO; GSM1671998
DR   GEO; GSM1672008
DR   GEO; GSM1672014
DR   GEO; GSM1672015
DR   GEO; GSM1672019
DR   GEO; GSM1672022
DR   GEO; GSM1672023
DR   GEO; GSM1672025
DR   GEO; GSM1672035
DR   GEO; GSM1672038
DR   GEO; GSM1672040
DR   GEO; GSM1672048
DR   GEO; GSM1672055
DR   ICLC; HTL02001
DR   IARC_TP53; 27579
DR   LiGeA; CCLE_246
DR   LINCS_LDP; LCL-1281
DR   PharmacoDB; SKMEL24_1395_2019
DR   PRIDE; PXD030304
DR   Progenetix; CVCL_0599
DR   PubChem_Cell_line; CVCL_0599
DR   Wikidata; Q54953969
RX   DOI=10.1007/978-1-4615-7228-2_39;
RX   PubMed=327080;
RX   PubMed=833871;
RX   PubMed=978138;
RX   PubMed=1067619;
RX   PubMed=3518877;
RX   PubMed=7017212;
RX   PubMed=7459858;
RX   PubMed=10709110;
RX   PubMed=12068308;
RX   PubMed=17308088;
RX   PubMed=20164919;
RX   PubMed=21654344;
RX   PubMed=21725359;
RX   PubMed=22460905;
RX   PubMed=24576830;
RX   PubMed=25485619;
RX   PubMed=25877200;
RX   PubMed=26405815;
RX   PubMed=26589293;
RX   PubMed=26673621;
RX   PubMed=27397505;
RX   PubMed=28196595;
RX   PubMed=30894373;
RX   PubMed=31068700;
RX   PubMed=35839778;
WW   https://www.mskcc.org/research-advantage/support/technology/tangible-material/human-melanoma-cell-line-sk-mel-24
WW   https://tcpaportal.org/mclp/
CC   Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).
CC   Part of: COSMIC cell lines project.
CC   Part of: MD Anderson Cell Lines Project.
CC   From: Memorial Sloan Kettering Cancer Center; New York; USA.
CC   Registration: Memorial Sloan Kettering Cancer Center Office of Technology Development; SK2003-078.
CC   Population: Caucasian.
CC   HLA typing: A*01:01,02:01; B*14:01,44:02; C*05:01,05:01 (PubMed=26589293).
CC   Microsatellite instability: Stable (MSS) (Sanger).
CC   Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Heterozygous (PubMed=12068308; PubMed=26405815; DepMap).
CC   Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Unspecified; Note=In promoter (PubMed=31068700).
CC   Sequence variation: Mutation; HGNC; 11998; TP53; None_reported; -; Zygosity=- (Cosmic-CLP; DepMap).
CC   Omics: Deep exome analysis.
CC   Omics: Deep quantitative proteome analysis.
CC   Omics: DNA methylation analysis.
CC   Omics: Protein expression by reverse-phase protein arrays.
CC   Omics: SNP array analysis.
CC   Omics: Transcriptome analysis by microarray.
CC   Omics: Transcriptome analysis by RNAseq.
CC   Genome ancestry: African=1.73%; Native American=0.82%; East Asian, North=1.82%; East Asian, South=0%; South Asian=0%; European, North=60.41%; European, South=35.21% (PubMed=30894373).
CC   Derived from site: Metastatic; Lymph node; UBERON=UBERON_0000027.
ST   Source(s): ATCC; Cosmic-CLP; PubMed=25877200
ST   Amelogenin: X,Y
ST   CSF1PO: 11
ST   D13S317: 12,13
ST   D16S539: 9,12
ST   D18S51: 16
ST   D21S11: 29,31.2
ST   D3S1358: 15
ST   D5S818: 9,13
ST   D7S820: 9,12
ST   D8S1179: 14,15
ST   FGA: 22,23
ST   Penta D: 9
ST   Penta E: 11,12
ST   TH01: 6,9
ST   TPOX: 11
ST   vWA: 15
DI   NCIt; C3224; Melanoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
SX   Male
AG   67Y
CA   Cancer cell line
DT   Created: 04-04-12; Last updated: 30-01-24; Version: 41
//
RX   DOI=10.1007/978-1-4615-7228-2_39;
RA   Houghton A.N., Oettgen H.F., Old L.J.;
RT   "Malignant melanoma. Current status of the search for melanoma-specific
RT   antigens.";
RL   (In) Immunodermatology. Comprehensive Immunology, Vol 7; Safai B., Good R.A. (eds.); pp.557-576; Springer; Boston (1981).
//
RX   PubMed=327080; DOI=10.1093/jnci/59.1.221;
RA   Fogh J., Fogh J.M., Orfeo T.;
RT   "One hundred and twenty-seven cultured human tumor cell lines
RT   producing tumors in nude mice.";
RL   J. Natl. Cancer Inst. 59:221-226(1977).
//
RX   PubMed=833871; DOI=10.1093/jnci/58.2.209;
RA   Fogh J., Wright W.C., Loveless J.D.;
RT   "Absence of HeLa cell contamination in 169 cell lines derived from
RT   human tumors.";
RL   J. Natl. Cancer Inst. 58:209-214(1977).
//
RX   PubMed=978138; DOI=10.1084/jem.144.4.873;
RA   Shiku H., Takahashi T., Oettgen H.F., Old L.J.;
RT   "Cell surface antigens of human malignant melanoma. II. Serological
RT   typing with immune adherence assays and definition of two new surface
RT   antigens.";
RL   J. Exp. Med. 144:873-881(1976).
//
RX   PubMed=1067619; DOI=10.1073/pnas.73.9.3278;
RA   Carey T.E., Takahashi T., Resnick-Silverman L.A., Oettgen H.F.,
RA   Old L.J.;
RT   "Cell surface antigens of human malignant melanoma: mixed
RT   hemadsorption assays for humoral immunity to cultured autologous
RT   melanoma cells.";
RL   Proc. Natl. Acad. Sci. U.S.A. 73:3278-3282(1976).
//
RX   PubMed=3518877; DOI=10.3109/07357908609038260;
RA   Fogh J.;
RT   "Human tumor lines for cancer research.";
RL   Cancer Invest. 4:157-184(1986).
//
RX   PubMed=7017212; DOI=10.1093/jnci/66.6.1003;
RA   Pollack M.S., Heagney S.D., Livingston P.O., Fogh J.;
RT   "HLA-A, B, C and DR alloantigen expression on forty-six cultured human
RT   tumor cell lines.";
RL   J. Natl. Cancer Inst. 66:1003-1012(1981).
//
RX   PubMed=7459858;
RA   Rousset M., Zweibaum A., Fogh J.;
RT   "Presence of glycogen and growth-related variations in 58 cultured
RT   human tumor cell lines of various tissue origins.";
RL   Cancer Res. 41:1165-1170(1981).
//
RX   PubMed=10709110; DOI=10.1002/(SICI)1097-0215(20000315)85:6<871::AID-IJC22>3.0.CO;2-O;
RA   McLaughlin P.M.J., Helfrich W., Kok K., Mulder M., Hu S.W.,
RA   Brinker M.G.L., Ruiters M.H.J., de Leij L.F.M.H., Buys C.H.C.M.;
RT   "The ubiquitin-activating enzyme E1-like protein in lung cancer cell
RT   lines.";
RL   Int. J. Cancer 85:871-876(2000).
//
RX   PubMed=12068308; DOI=10.1038/nature00766;
RA   Davies H., Bignell G.R., Cox C., Stephens P.J., Edkins S., Clegg S.,
RA   Teague J.W., Woffendin H., Garnett M.J., Bottomley W., Davis N.,
RA   Dicks E., Ewing R., Floyd Y., Gray K., Hall S., Hawes R., Hughes J.,
RA   Kosmidou V., Menzies A., Mould C., Parker A., Stevens C., Watt S.,
RA   Hooper S., Wilson R., Jayatilake H., Gusterson B.A., Cooper C.S.,
RA   Shipley J.M., Hargrave D., Pritchard-Jones K., Maitland N.J.,
RA   Chenevix-Trench G., Riggins G.J., Bigner D.D., Palmieri G., Cossu A.,
RA   Flanagan A.M., Nicholson A., Ho J.W.C., Leung S.Y., Yuen S.T.,
RA   Weber B.L., Seigler H.F., Darrow T.L., Paterson H.F., Marais R.,
RA   Marshall C.J., Wooster R., Stratton M.R., Futreal P.A.;
RT   "Mutations of the BRAF gene in human cancer.";
RL   Nature 417:949-954(2002).
//
RX   PubMed=17308088; DOI=10.1158/0008-5472.CAN-06-3311;
RA   Shields J.M., Thomas N.E., Cregger M., Berger A.J., Leslie M.,
RA   Torrice C., Hao H.-L., Penland S., Arbiser J.L., Scott G.A., Zhou T.,
RA   Bar-Eli M., Bear J.E., Der C.J., Kaufmann W.K., Rimm D.L.,
RA   Sharpless N.E.;
RT   "Lack of extracellular signal-regulated kinase mitogen-activated
RT   protein kinase signaling shows a new type of melanoma.";
RL   Cancer Res. 67:1502-1512(2007).
//
RX   PubMed=20164919; DOI=10.1038/nature08768;
RA   Bignell G.R., Greenman C.D., Davies H., Butler A.P., Edkins S.,
RA   Andrews J.M., Buck G., Chen L., Beare D., Latimer C., Widaa S.,
RA   Hinton J., Fahey C., Fu B.-Y., Swamy S., Dalgliesh G.L., Teh B.T.,
RA   Deloukas P., Yang F.-T., Campbell P.J., Futreal P.A., Stratton M.R.;
RT   "Signatures of mutation and selection in the cancer genome.";
RL   Nature 463:893-898(2010).
//
RX   PubMed=21654344; DOI=10.1097/CMR.0b013e328343a1d6;
RA   Molhoek K.R., Shada A.L., Smolkin M., Chowbina S., Papin J.,
RA   Brautigan D.L., Slingluff C.L. Jr.;
RT   "Comprehensive analysis of receptor tyrosine kinase activation in
RT   human melanomas reveals autocrine signaling through IGF-1R.";
RL   Melanoma Res. 21:274-284(2011).
//
RX   PubMed=21725359; DOI=10.1038/onc.2011.250;
RA   Xing F., Persaud Y., Pratilas C.A., Taylor B.S., Janakiraman M.,
RA   She Q.-B., Gallardo H., Liu C., Merghoub T., Hefter B., Dolgalev I.,
RA   Viale A.J., Heguy A., de Stanchina E., Cobrinik D., Bollag G.,
RA   Wolchok J.D., Houghton A.N., Solit D.B.;
RT   "Concurrent loss of the PTEN and RB1 tumor suppressors attenuates RAF
RT   dependence in melanomas harboring (V600E)BRAF.";
RL   Oncogene 31:446-457(2012).
//
RX   PubMed=22460905; DOI=10.1038/nature11003;
RA   Barretina J.G., Caponigro G., Stransky N., Venkatesan K., Margolin A.A.,
RA   Kim S., Wilson C.J., Lehar J., Kryukov G.V., Sonkin D., Reddy A.,
RA   Liu M., Murray L., Berger M.F., Monahan J.E., Morais P., Meltzer J.,
RA   Korejwa A., Jane-Valbuena J., Mapa F.A., Thibault J., Bric-Furlong E.,
RA   Raman P., Shipway A., Engels I.H., Cheng J., Yu G.-Y.K., Yu J.-J.,
RA   Aspesi P. Jr., de Silva M., Jagtap K., Jones M.D., Wang L., Hatton C.,
RA   Palescandolo E., Gupta S., Mahan S., Sougnez C., Onofrio R.C.,
RA   Liefeld T., MacConaill L.E., Winckler W., Reich M., Li N.-X., Mesirov J.P.,
RA   Gabriel S.B., Getz G., Ardlie K., Chan V., Myer V.E., Weber B.L.,
RA   Porter J., Warmuth M., Finan P., Harris J.L., Meyerson M.L., Golub T.R.,
RA   Morrissey M.P., Sellers W.R., Schlegel R., Garraway L.A.;
RT   "The Cancer Cell Line Encyclopedia enables predictive modelling of
RT   anticancer drug sensitivity.";
RL   Nature 483:603-607(2012).
//
RX   PubMed=24576830; DOI=10.1158/0008-5472.CAN-13-2625;
RA   Nissan M.H., Pratilas C.A., Jones A.M., Ramirez R., Won H., Liu C.-L.,
RA   Tiwari S., Kong L., Hanrahan A.J., Yao Z., Merghoub T., Ribas A.,
RA   Chapman P.B., Yaeger R., Taylor B.S., Schultz N., Berger M.F.,
RA   Rosen N., Solit D.B.;
RT   "Loss of NF1 in cutaneous melanoma is associated with RAS activation
RT   and MEK dependence.";
RL   Cancer Res. 74:2340-2350(2014).
//
RX   PubMed=25485619; DOI=10.1038/nbt.3080;
RA   Klijn C., Durinck S., Stawiski E.W., Haverty P.M., Jiang Z.-S.,
RA   Liu H.-B., Degenhardt J., Mayba O., Gnad F., Liu J.-F., Pau G.,
RA   Reeder J., Cao Y., Mukhyala K., Selvaraj S.K., Yu M.-M., Zynda G.J.,
RA   Brauer M.J., Wu T.D., Gentleman R.C., Manning G., Yauch R.L.,
RA   Bourgon R., Stokoe D., Modrusan Z., Neve R.M., de Sauvage F.J.,
RA   Settleman J., Seshagiri S., Zhang Z.-M.;
RT   "A comprehensive transcriptional portrait of human cancer cell
RT   lines.";
RL   Nat. Biotechnol. 33:306-312(2015).
//
RX   PubMed=25877200; DOI=10.1038/nature14397;
RA   Yu M., Selvaraj S.K., Liang-Chu M.M.Y., Aghajani S., Busse M.,
RA   Yuan J., Lee G., Peale F.V., Klijn C., Bourgon R., Kaminker J.S.,
RA   Neve R.M.;
RT   "A resource for cell line authentication, annotation and quality
RT   control.";
RL   Nature 520:307-311(2015).
//
RX   PubMed=26405815; DOI=10.1371/journal.pone.0138210;
RA   Capaldo B.J., Roller D.G., Axelrod M.J., Koeppel A.F., Petricoin E.F. III,
RA   Slingluff C.L. Jr., Weber M.J., Mackey A.J., Gioeli D., Bekiranov S.;
RT   "Systems analysis of adaptive responses to MAP kinase pathway blockade
RT   in BRAF mutant melanoma.";
RL   PLoS ONE 10:E0138210-E0138210(2015).
//
RX   PubMed=26589293; DOI=10.1186/s13073-015-0240-5;
RA   Scholtalbers J., Boegel S., Bukur T., Byl M., Goerges S., Sorn P.,
RA   Loewer M., Sahin U., Castle J.C.;
RT   "TCLP: an online cancer cell line catalogue integrating HLA type,
RT   predicted neo-epitopes, virus and gene expression.";
RL   Genome Med. 7:118.1-118.7(2015).
//
RX   PubMed=26673621; DOI=10.18632/oncotarget.6548;
RA   Roller D.G., Capaldo B.J., Bekiranov S., Mackey A.J., Conaway M.R.,
RA   Petricoin E.F. III, Gioeli D., Weber M.J.;
RT   "Combinatorial drug screening and molecular profiling reveal diverse
RT   mechanisms of intrinsic and adaptive resistance to BRAF inhibition in
RT   V600E BRAF mutant melanomas.";
RL   Oncotarget 7:2734-2753(2016).
//
RX   PubMed=27397505; DOI=10.1016/j.cell.2016.06.017;
RA   Iorio F., Knijnenburg T.A., Vis D.J., Bignell G.R., Menden M.P.,
RA   Schubert M., Aben N., Goncalves E., Barthorpe S., Lightfoot H.,
RA   Cokelaer T., Greninger P., van Dyk E., Chang H., de Silva H., Heyn H.,
RA   Deng X.-M., Egan R.K., Liu Q.-S., Mironenko T., Mitropoulos X.,
RA   Richardson L., Wang J.-H., Zhang T.-H., Moran S., Sayols S.,
RA   Soleimani M., Tamborero D., Lopez-Bigas N., Ross-Macdonald P.,
RA   Esteller M., Gray N.S., Haber D.A., Stratton M.R., Benes C.H.,
RA   Wessels L.F.A., Saez-Rodriguez J., McDermott U., Garnett M.J.;
RT   "A landscape of pharmacogenomic interactions in cancer.";
RL   Cell 166:740-754(2016).
//
RX   PubMed=28196595; DOI=10.1016/j.ccell.2017.01.005;
RA   Li J., Zhao W., Akbani R., Liu W.-B., Ju Z.-L., Ling S.-Y., Vellano C.P.,
RA   Roebuck P., Yu Q.-H., Eterovic A.K., Byers L.A., Davies M.A., Deng W.-L.,
RA   Gopal Y.N.V., Chen G., von Euw E.M., Slamon D.J., Conklin D.,
RA   Heymach J.V., Gazdar A.F., Minna J.D., Myers J.N., Lu Y.-L., Mills G.B.,
RA   Liang H.;
RT   "Characterization of human cancer cell lines by reverse-phase protein
RT   arrays.";
RL   Cancer Cell 31:225-239(2017).
//
RX   PubMed=30894373; DOI=10.1158/0008-5472.CAN-18-2747;
RA   Dutil J., Chen Z.-H., Monteiro A.N.A., Teer J.K., Eschrich S.A.;
RT   "An interactive resource to probe genetic diversity and estimated
RT   ancestry in cancer cell lines.";
RL   Cancer Res. 79:1263-1273(2019).
//
RX   PubMed=31068700; DOI=10.1038/s41586-019-1186-3;
RA   Ghandi M., Huang F.W., Jane-Valbuena J., Kryukov G.V., Lo C.C.,
RA   McDonald E.R. III, Barretina J.G., Gelfand E.T., Bielski C.M., Li H.-X.,
RA   Hu K., Andreev-Drakhlin A.Y., Kim J., Hess J.M., Haas B.J., Aguet F.,
RA   Weir B.A., Rothberg M.V., Paolella B.R., Lawrence M.S., Akbani R.,
RA   Lu Y.-L., Tiv H.L., Gokhale P.C., de Weck A., Mansour A.A., Oh C.,
RA   Shih J., Hadi K., Rosen Y., Bistline J., Venkatesan K., Reddy A.,
RA   Sonkin D., Liu M., Lehar J., Korn J.M., Porter D.A., Jones M.D.,
RA   Golji J., Caponigro G., Taylor J.E., Dunning C.M., Creech A.L.,
RA   Warren A.C., McFarland J.M., Zamanighomi M., Kauffmann A.,
RA   Stransky N., Imielinski M., Maruvka Y.E., Cherniack A.D.,
RA   Tsherniak A., Vazquez F., Jaffe J.D., Lane A.A., Weinstock D.M.,
RA   Johannessen C.M., Morrissey M.P., Stegmeier F., Schlegel R.,
RA   Hahn W.C., Getz G., Mills G.B., Boehm J.S., Golub T.R., Garraway L.A.,
RA   Sellers W.R.;
RT   "Next-generation characterization of the Cancer Cell Line
RT   Encyclopedia.";
RL   Nature 569:503-508(2019).
//
RX   PubMed=35839778; DOI=10.1016/j.ccell.2022.06.010;
RA   Goncalves E., Poulos R.C., Cai Z.-X., Barthorpe S., Manda S.S., Lucas N.,
RA   Beck A., Bucio-Noble D., Dausmann M., Hall C., Hecker M., Koh J.,
RA   Lightfoot H., Mahboob S., Mali I., Morris J., Richardson L.,
RA   Seneviratne A.J., Shepherd R., Sykes E., Thomas F., Valentini S.,
RA   Williams S.G., Wu Y.-X., Xavier D., MacKenzie K.L., Hains P.G., Tully B.,
RA   Robinson P.J., Zhong Q., Garnett M.J., Reddel R.R.;
RT   "Pan-cancer proteomic map of 949 human cell lines.";
RL   Cancer Cell 40:835-849.e8(2022).
//